secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2023-04-24T23:59:59+00:00
Accession:  0001171843-23-002480
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics appoints Richard S. Lindahl to Board and Audit Committee chair
--------------------------------------------------------------------------------

- Richard S. Lindahl appointed as Class III director effective April 21, 2023; term expires at 2023 annual meeting.
- Also appointed chairman of Audit Committee; qualifies as independent director and audit committee financial expert.
- Compensation: $45,000 cash retainer, $10,000 additional for Audit Committee chair; 50,000 share option award vesting monthly over four years.
- No family relationships or reportable transactions with the Company or its officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323002480/0001171843-23-002480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323002480/f8k_042423.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-002480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer